Eli Lilly announced that solanezumab, its experimental drug for Alzheimer’s, failed to improve cognition in a large clinical trial. Here are some lessons from these failures. Now Juno has announced that two more patients have died. JCAR015, originally developed at Memorial Sloan-Kettering Cancer Center in New York, may just be more toxic than other treatments (they’re called CARTs, for chimeric antigen receptor T-cells). That doesn’t mean that Juno’s CARTs from at the Fred Hutchinson Cancer Research Center in Seattle are equally dangerous.

Source: Forbes November 23, 2016 19:50 UTC